Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
54.9M
-
Shares change
-
-10.8M
-
Total reported value, excl. options
-
$196M
-
Value change
-
-$86.4M
-
Put/Call ratio
-
0.26
-
Number of buys
-
72
-
Number of sells
-
-70
-
Price
-
$3.57
Significant Holders of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) as of Q3 2024
185 filings reported holding FULC - Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54.9M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.2M shares), BlackRock, Inc. (5.71M shares), TCG Crossover Management, LLC (5.25M shares), Nantahala Capital Management, LLC (4.78M shares), VANGUARD GROUP INC (3.27M shares), TRV GP IV, LLC (2.34M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2M shares), FMR LLC (1.72M shares), STATE STREET CORP (1.68M shares), and DIMENSIONAL FUND ADVISORS LP (1.42M shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.